• RED RIBBON
• /
• s.55
• /
• pp.16-17
• /
• 2003

올해는 어느 해보다 수혈관련 사건이 많이 일어났다. 그 여파로 오염된 혈액이 혈액제제로 사용됐음을 문제삼는 기사가 유난히 많았던 한 해였다. 언론에서 보도하는 것처럼 혈액제제는 정말 신뢰할 수 없는 것인가?

• The Korean Journal of Blood Transfusion
• /
• v.23 no.2
• /
• pp.145-151
• /
• 2012

배경: 채혈 후 제제 경과시간에 따른 동결혈장의 혈액응고인자의 활성도와 이에 영향을 미치는 요인을 분석하여, 혈액응고인자제제의 원료혈장의 사용범위를 확장 가능한지 확인하고자 동결혈장의 채혈시간과 응고인자 특성을 측정하였다. 방법: ALT 부적격 혈장을 채혈 후 동결시간의 특성에 따라 4단계로 구분하였고, 6종류의 혈액 응고인자 활성도와 혈액형을 검사하였고, SAS 9.2 프로그램을 사용하여 통계처리 하였다. 결과: 혈액제제간 FVIII 활성도를 분석한 결과 PL-A>FFP>FP(8-24)${\approx}$FP(24-72) 순으로 유의하게 낮아졌고 혈액형에 따라서는 AB형이 제일 높고, O형이 제일 낮았다. 대한적십자사의 원료혈장에 대한 FVIII 활성 품질기준을 적용할 경우 PL-A, FFP와 FP24는 각각 85.0%와 82.5%로 적합하였다. 캐나다 퀘백 주처럼 FP24의 FVIII 활성이 0.52 IU/mL 이상을 적용할 경우 PL-A, FFP와 FP24는 각각 95.0%, 96.3%, 82.6%로 적합하였다. 또한 FP(8-24)의 A형과 AB형, FP(24-72)의 경우 AB형이 각각 82.1%, 83.3%, 100%로 적합하였다. 결론: 혈액응고인자제제용 원료혈장의 범위는 외국의 기준에 비추어 채혈 후 24시간 내에 동결된 혈장(FP24)으로 확대 사용이 가능하다. 이를 위해서는 채혈 후 동결시간과 혈액응고인자에 대한 품질기준을 유럽약전 또는 WHO 가이드라인과 비교하여 완화하는 것이 필요하다.

• Korean Journal of Clinical Laboratory Science
• /
• v.54 no.1
• /
• pp.73-77
• /
• 2022

Blood products (BPs) can only be obtained through blood donation and hence represent a finite resource. BPs should therefore be used conservatively. However, BPs are being used indiscriminately without evidence. The purpose of this study was to evaluate the reasons for the use of BPs and their appropriateness. The investigation was carried out based on hemoglobin levels. Data were obtained from Nov 1, 2020, to Oct 31, 2021, from a hospital's OCS/EMR systems. The BPs were dispensed in 21,303 cases, and the number of hemoglobin levels >7.0 g/dL or higher among red blood cell drugs used by each treatment department was 1,173 (>7.0 g/dL). The misuse of blood transfusions is increasing social costs, with the adequacy of transfusion becoming increasingly important. Hence, each medical institution should review the transfusion guideline evaluation index, check the status of the release of BPs, and institute educational programs covering transfusion guidelines and continually evaluate their adequacy.

• RED RIBBON
• /
• s.58
• /
• pp.22-25
• /
• 2004

국내에서 수혈되는 혈액에 대해서도 선진국에서 실시하고 있는 핵산증폭검사가 올해 하반기부터 적용될 예정이다. 핵산증폭검사의 실시로 혈액제제로 안전성은 그 어느 때보다도 높아질 예정이다.

• RED RIBBON
• /
• s.15
• /
• pp.14-16
• /
• 1997

80년대 중반이후의 혈액관리 방법의 개선은 대부분 에이즈 바이러스 때문이라고 하여도 과언이 아닐 정도이다. 그것은 수혈 및 혈장분획제제 투여에 의한 에이즈 발병 및 치사율이 그만큼 높았기 때문이다.

• The Korean Journal of Blood Transfusion
• /
• v.29 no.3
• /
• pp.262-272
• /
• 2018

Background: Massive hemorrhage due to trauma is one of the major causes of death in trauma patients, and the quick supply of appropriate blood products is critical in order to reduce the mortality rate. We introduced a massive transfusion protocol (MTP) for safe and rapid transfusion of trauma patients. Using records collected since its adoption, we compared the characteristics of MTP applied group (MTP group) and MTP not applied group (non-MTP group) to determine whether there is an indicator for predicting patients to be treated with MTP. Methods: We retrospectively reviewed the electronic medical records and laboratory findings of patients who received massive transfusions in the trauma emergency room of a single tertiary hospital from February to August 2018. We analyzed various laboratory test results, the amount and ratio of the transfused blood products, and the time required for blood products to be released for the MTP group and the non-MTP group. Results: Of the 54 trauma patients who received massive transfusions, 31 were in the MTP group and 22 in the non-MTP group. There was no significant difference in initial vital signs (except blood pressure) and laboratory test results. Also there was no difference in the amount and ratio of blood products, but the time required for blood product release was shorter in the MTP group. Conclusion: There was no significant difference in clinical findings such as initial vital signs and laboratory test results between the MTP and non-MTP groups, but required blood products were prepared and released more quickly for the MTP group.

• The Korean Journal of Blood Transfusion
• /
• v.29 no.3
• /
• pp.253-261
• /
• 2018

Background: A massive blood transfusion (MT) requires significant efforts by the Blood Bank. This study examined blood product use in MT and emergency O Rh Positive red cells (O RBCs) available directly for emergency patients from the Trauma Center in Ajou University Hospital. Methods: MT was defined as a transfusion of 10 or more RBCs within 24 hours. The extracted data for the total RBCs, fresh frozen plasma (FFP), platelets (PLTs, single donor platelets (SDP) and random platelet concentrates (PC)) issued from Blood Bank between March 2016 and November 2017 from Hospital Information System were reviewed. SDP was considered equivalent to 6 units of PC. Results: A total of 345 MTs, and 6233/53268 (11.7%) RBCs, 4717/19376 (24.3%) FFP, and 4473/94166 (4.8%) PLTs were used in MT (P<0.001). For the RBC products in MT and non-MT transfusions, 28.0% and 34.1% were group A; 27.1% and 26.0% were group B; 37.3% and 29.7% were group O, and 7.5% and 10.2% were group AB (P<0.001). The ratios of RBC:FFP:PLT use were 1:0.76:0.72 in MT and 1:0.31:1.91 in non-MT (P<0.001). A total of 461 O RBCs were used in 36.2% (125/345) of MT cases and the number of O RBCs transfused per patient ranged from 1 to 18. Conclusion: RBCs with the O blood group are most used for MT. Ongoing education of clinicians to minimize the overuse of emergency O RBCs in MT is required. A procedure to have thawed plasma readily available in MT appears to be of importance because FFP was used frequently in MT.

• 월간산업보건
• /
• s.180
• /
• pp.47-50
• /
• 2003

• RED RIBBON
• /
• s.67
• /
• pp.24-25
• /
• 2005

최근 항체미형성기의 오염혈액을 2003년 8월 수혈받은 2명이 에이즈의 원인병원체인 HIV(인면역결핍바이러스)에 감염된 사실이 언론에 발표되었다. 다행스럽게도 수혈감염자로부터 2차 감염은 이루어지지 않았으나 얼마 전 HIV 항체미형성기의 혈장을 원료로 한 알부민제제 시판 논란과 더불어 일반 국민들은 국가혈액공급의 안전에 큰 불안을 갖게 되었다.

• Proceedings of the KSCN Conference
• /
• 1997.05a
• /
• pp.47-47
• /
• 1997